NEWS RELEASE
May 22, 2024
Launch of Vyxeos® Combination for I.V. Injection for the Treatment of
High-risk AML in Japan
Kyoto, Japan, May 22, 2024 - Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters, Kyoto; President, Toru Nakai) announced today that it has launched Vyxeos® Combination for I.V. Injection (Daunorubicin hydrochloride/cytarabine liposomal drug for injection) for the treatment of high-risk acute myeloid leukemia (AML) in Japan. This follows the marketing approval of Vyxeos®, which was granted by the Ministry of Health, Labour and Welfare (MHLW) on March 26, 2024.
AML is a disease of clonal proliferation of immature myeloid cells, and results from genetic abnormalities in myeloblasts which are immature blood cells. The uncontrollable growth of leukemia cells in the bone marrow prevents the production of normal blood which results in various symptoms such as infections and bleeding.1 Although multiple AML drugs have been launched in recent years and the outcomes for some patient groups have improved, many patients still do not have long- term survival. Novel therapeutic agents with greater efficacy are needed.2
Vyxeos® is a liposomal formulation of a fixed combination of cytarabine and daunorubicin, the standard drugs for AML treatment, at 5:1 molar ratio. The 5:1 molar ratio has been shown to maximize synergistic antitumor activity in AML. After the drug is taken up by leukemia cells in the bone marrow, cytarabine and daunorubicin are released to exert its anti-tumor effect.
Nippon Shinyaku acquired a license for Vyxeos® from Jazz Pharmaceuticals plc (Headquarters: Dublin, Ireland, Chairman and CEO: Bruce C. Cozadd) on March 30, 2017. Vyxeos® is approved for the treatment of therapy-related AML and AML with myelodysplastic changes in more than 31 countries or regions around the world, including Europe and the United States.
Nippon Shinyaku believes that it will contribute to the treatment of high-risk AML* by delivering Vyxeos® appropriately to healthcare professionals and their patients who need it.
-
The definition of high-risk AML is if any of the following conditions below apply. ・therapy-related AML
・AML with a history of myelodysplastic syndromes (MDS) ・de novo AML with MDS-related cytogenetic abnormalities
・AML with a history of chronic myelomonocytic leukemia (CMML)
References
- Japanese Society of Hematology. Practical Guidelines for Hematological Malignancies, 2023, Kanehara & Co., Ltd. (Japanese only).
- Gurnari C et al. Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia. Int J Mol Sci. 2020; 21(22):8505.
1 / 2
Summary of Vyxeos®
Brand name | Vyxeos® Combination for I.V. Injection |
Generic name | Daunorubicin hydrochloride/cytarabine liposomal drug for injection |
Date of approval | March 26, 2024 |
Date of NHI reimbursement | May 22, 2024 |
price listing | |
Date of launch | May 22, 2024 |
Number of approval | 30600AMX00112000 |
Dosage Forms and Strengths | Freeze-dried preparation for injection containing 47mg of daunorubicin |
hydrochloride (44mg as daunorubicin) and 100mg of cytarabine in 1 vial | |
Indication | High-risk acute myeloid leukemia |
(1) Remission induction therapy | |
Usually, as remission induction therapy, 100 units (44mg as | |
daunorubicin and 100mg as cytarabine)/m2 (body surface area) of | |
Vyxeos® Combination for I.V. Injection shall be administered over 90 | |
minutes once daily for up to two cycles. | |
This drug shall be intravenously administered by drip infusion on Days | |
1, 3, and 5 of Cycle 1. This drug shall be intravenously administered by | |
drip infusion on Days 1 and 3 of Cycle 2 to patients who do not achieve | |
remission during Cycle 1, if there are no unacceptable toxicities, two to | |
five weeks after the start of Cycle 1. | |
(2) Consolidation therapy | |
Dosage and Administration | Usually, as consolidation therapy, 65 units (29mg as daunorubicin and |
65mg as cytarabine)/m2 (body surface area) of Vyxeos® Combination for | |
I.V. Injection shall be administered over 90 minutes once daily for up to | |
two cycles. | |
This drug shall be intravenously administered by drip infusion on Days | |
1 and 3 of Cycle 1, five to eight weeks after the start of the last remission | |
induction therapy. This drug shall be intravenously administered by drip | |
infusion on Days 1 and 3 of Cycle 2 to patients without disease | |
progression after the start of administration of Cycle 1, if there are no | |
unacceptable toxicities, five to eight weeks after the start of Cycle 1 of | |
the consolidation therapy. | |
One dose unit of this drug contains 0.44mg of daunorubicin and 1mg of | |
cytarabine. | |
NHI reimbursement price | JPY 877,877/vial |
Packaging unit | 1 vial |
About Nippon Shinyaku
Based on Nippon Shinyaku's business philosophy, "Helping people lead healthier, happier lives," we aim to be an organization trusted by the community through creating unique medicines that will bring hope to patients and families suffering from illness. Please visit our website (https://www.nippon-shinyaku.co.jp/english/) for products or detailed information.
Contact
Corporate Communications Dept., Nippon Shinyaku Co., Ltd.
FAX: +81-75-321-9128
2 / 2
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Nippon Shinyaku Co. Ltd. published this content on 22 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 May 2024 01:02:02 UTC.